Knight Therapeutics sees 2023 revenue C$310M-C$330M

Knight provides guidance on revenues on a non-GAAP basis. This is due to both the difficulty in predicting Argentinian inflation rates and its IAS 29 impact. For fiscal 2023, Knight has updated its financial guidance on revenues and expects to generate between $310 million to $330 million in revenues an increase of $10 million on the lower and upper end of the range. The adjusted EBITDA is expected to be between 16% to 17% of revenues. The increase in the financial outlook is primarily due to an improvement in LATAM currencies against the Canadian dollar in the second quarter of 2023.